Avitinib maleate

Avitinib maleate (CAS No.: 1557268-88-8) is a pyrrolopyrimidine-based, third-generation irreversible inhibitor of epidermal growth factor receptor (EGFR) that is widely utilized in oncology-focused research to interrogate EGFR-driven signaling pathways. It exhibits potent inhibitory activity against mutant EGFR variants, including L858R and T790M, as well as wild-type EGFR, with activity observed in the nanomolar range, and functions through covalent binding that leads to sustained suppression of receptor kinase activity. In addition to its EGFR-targeting properties, Avitinib maleate also inhibits Bruton's tyrosine kinase (BTK), reducing BTK phosphorylation and promoting apoptosis in relevant cellular models such as mantle cell lymphoma, thereby providing a dual-target framework for studying crosstalk between EGFR- and BTK-mediated signaling networks. This compound is commonly applied in in vitro cell-based assays and in vivo experimental systems to investigate mechanisms of kinase inhibition, resistance mutations, and pathway modulation, with dosing and concentration parameters varying according to specific experimental designs and research objectives.